Lipocine Inc
NASDAQ:LPCN

Watchlist Manager
Lipocine Inc Logo
Lipocine Inc
NASDAQ:LPCN
Watchlist
Price: 7.58 USD 0.86% Market Closed
Market Cap: 42.1m USD

During the last 3 months Lipocine Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 135% over this period (open performance analysis).

The last transaction was made on May 25, 2023 by Patel Mahesh V. , who bought 43.8k USD worth of LPCN shares.

Last Transactions:
Patel Mahesh V.
$+43.8k
Patel Mahesh V.
$+2.8k
Ono Richard Dana
$+79.9
Patel Mahesh V.
$+970.5
Papapetropoulos Spyros
$+601.1
Patel Mahesh V.
$+1.7k
Patel Mahesh V.
$+2.4k
Fogarty Krista
$+632.1
Patel Mahesh V.
$+2.3k
Patel Mahesh V.
$+1.6k
Higuchi John W.
$-134.5
Patel Mahesh V.
$-1.2k
Brown Morgan R
$-669.6
Patel Mahesh V.
$-4k
Brown Morgan R
$-1.6k
Higuchi John W.
$+4.1k
Patel Mahesh V.
$+902.4
Patel Mahesh V.
$+586.9
Patel Mahesh V.
$-1k
Brown Morgan R
$-416.4
Patel Mahesh V.
$+32
Patel Mahesh V.
$+116
Bass Gregory Brooks
$-767.5
Patel Mahesh V.
$-1.2k
Ono Richard Dana
$-176.8
Fink Jeffrey Arvin
$-191.1
Brown Morgan R
$-573.3
Hill Stephen A
$-257
Higuchi John W.
$+3.7k
Patel Mahesh V.
$+1.4k
View All Transactions

During the last 3 months Lipocine Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 135% over this period (open performance analysis).

The last transaction was made on May 25, 2023 by Patel Mahesh V. , who bought 43.8k USD worth of LPCN shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Lipocine Inc
Insider Trading Chart

Lipocine Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Lipocine Inc
Last Insider Transactions

Global
Insiders Monitor

Lipocine Inc
Glance View

Market Cap
41.1m USD
Industry
Pharmaceuticals

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 13 full-time employees. The company went IPO on 2014-03-21. The firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The company has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The firm's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

LPCN Intrinsic Value
2.82 USD
Overvaluation 63%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top